Alps Advisors Inc Agenus Inc Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$1.45 - $2.95 $8,408 - $17,107	-5,799 Reduced 2.81%	200,824 $305,000
Q4 2022 Feb 14, 2023	BUY	$2.02 - $3.25 $105,112 - $169,117	52,036 Added 33.66%	206,623 $495,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.14 $11,256 - $18,033	-5,743 Reduced 3.58%	154,587 $317,000
Q2 2022 Aug 11, 2022	SELL	$1.3 - $2.64 $135,145 - $274,449	-103,958 Reduced 39.34%	160,330 $311,000
Q1 2022 May 16, 2022	SELL	$2.35 - $3.47 $77,432 - $114,336	-32,950 Reduced 11.09%	264,288 $650,000
Q4 2021 Feb 09, 2022	BUY	$2.92 - $5.74 $867,934 - $1.71 Million	297,238 New	297,238 $957,000
Q2 2020 Aug 05, 2020	SELL	$2.29 - $4.24 $571,888 - $1.06 Million	-249,733 Closed	0 $0
Q1 2020 May 06, 2020	SELL	$1.92 - $4.39 $55,900 - $127,814	-29,115 Reduced 10.44%	249,733 $612,000
Q4 2019 Feb 07, 2020	BUY	$2.41 - $4.4 $12,175 - $22,228	5,052 Added 1.85%	278,848 $1.14 Million
Q3 2019 Nov 04, 2019	SELL	$2.17 - $3.14 $15,632 - $22,620	-7,204 Reduced 2.56%	273,796 $706,000
Q2 2019 Aug 07, 2019	BUY	$2.53 - $3.04 $710,930 - $854,240	281,000 New	281,000 $843,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.